

From N-of-1 to N-of-all: Clinical Decision Making in the Era of Big Data and Personalized Medicine

Mia Levy, MD, PhD
National Cancer Policy Forum
10.30.2018

Disclosures

- **Consulting/Advisory:** GenomOncology, Personalis, Roche
- **Research funding:** Pfizer, BMS, GenomOncology
- **Equity:** GenomOncology, Personalis

Work presented today funded in part by research grants from:







If You Can't
Measure It,
You Can't
Improve It

(William Thomson, Lord Kelvin)

AND WARREN HERE
IS IN CHARGE OF
OUR GUT FEELINGS



The background features a light blue grid with white circuit-like lines and a horizontal band of binary code (0s and 1s) across the middle.

Implementation Research: the scientific study of barriers to and methods of promoting the systematic application of research findings into practice

Evolution of Clinical Decision Support

Evidence Driven
Protocol Driven
Pathway Driven
Data Driven?

Riding the Tsunami of Genomic Data



Evolution of testing strategies

Single mutation -> Hot spot panels -> NGS

Decision Support



Which test to order?



My Lab Results....

**This is
NORMAL??**

(NOT)

How to
interpret &
report
results?

A Venn diagram with three overlapping circles. The top-left circle is purple and labeled 'Best available evidence'. The top-right circle is red and labeled 'Doctor's judgment'. The bottom circle is blue and labeled 'Patient values'. The central intersection of all three circles is dark blue and labeled 'EBM'. The background is a soft-focus image of green leaves.

Best
available
evidence

Doctor's
judgment

EBM

Patient
values

How to apply
results to patient
management?



EXPERT SYSTEMS



My Cancer Genome knowledge driven clinical decision support

Clinically Integrated Solutions

Publically Available Resources



Website

>2.5M page views,
213 countries

My
Cancer
Genome

Vanderbilt
EHR info
button

>8436 patients

Laboratory
Reporting
Tool


>23000 specimens
25 institutions

Molecular Consult Tool
Clinical Trial Matching

Vanderbilt Experience

8,436 Tumors Genotyped by
Vanderbilt-Ingram Cancer Center


979 Total Genotyped Patients Enrolled
on Interventional Clinical Trials



21,599 Variants of Uncertain
Significance for Discovery Research

4,694 Total Patients Enrolled on Precision Oncology Clinical Trials

Prospective Randomized Trial evaluating impact of CT-matching



Embedded versus Tethered



Built-in



Brought-in



Balancing EHR documentation innovation with Provider Burnout



Acknowledgements

Christine Lovly

Christine Micheel

Ingrid Anderson

Michele Lenoue-Newton

Neha Jain

Lucy Wang

Tom Sticker

Justin Balko

Kim Dahlman

Travis Osterman

Scott Sobecki

Joey Schneider

Mik Cantrell

Ross Oreto

Ari Taylor

MCG Contributors

MCG Alumni

GENIE Consortium

GenomOncology

Koman Scholar Grant

I3P IGNITE grant

And many more...



Thank You

mia.levy@Vanderbilt.edu